Burst!Three good news from the new crown vaccine


Original title: Burst!Three good news from the new crown vaccine


[Suddenly! Three good news from the new crown vaccine]Fauci said that the vaccine can be widely used in the months after early 2021; AstraZeneca has resumed laboratory testing of the new crown vaccine worldwide; Johnson & Johnson expects to restart vaccine trials on Monday or Tuesday. (China Fund News)

The global new crown vaccine reported three positives last night.

Fauci said that the vaccine could be widely used in the months after the beginning of 2021; AstraZeneca resumed laboratory testing of the new crown vaccine on a global scale;JohnsonVaccine trials are expected to restart on Monday or Tuesday.

The overseas epidemic situation is still very severe. The WHO said that the global epidemic is at a critical juncture, and the number of cases in too many countries is increasing exponentially.

The cumulative number of confirmed cases in the United States has exceeded 8.46 million, and the number of confirmed cases in a single day is about to approach the highest record. However, Trump was revealed that he had not participated in the White House new crown for several months.jobsGroup ofmeeting

Bill Gates also warned that even a year later, the world will not return to normal.

Under the influence of the epidemic and the stalemate of the stimulus plan, US stocks were mixed last night, ending the three-day weekly rally.

  Fauci: Vaccines can be widely used in the months after early 2021U.S. Covid-19 cases surge, but Trump is absent from White House Covid-19work groupLong meeting

Last night, there was good news on the US new crown vaccine schedule.

Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the vaccine is expected to be widely used in the months after early 2021. Previously, on the 14th local time of this month, Fauci said that ordinary Americans would not be able to get the new crown vaccine until April 2021.

Fauci said the new crown vaccine looks promising.

But Fauci also said that he was worried about the current rate of new coronary pneumonia infections and worried about the surge in new coronary cases in the United States.

Recently, Fauci inacceptThe interview also mentioned, “As people enter the cold autumn and cold winter months, if the situation cannot be reversed and changed, they will face some truly more serious problems that we have never encountered before. We really want to avoid the past. .”

According to data from Johns Hopkins University, on October 22, there were 76,195 newly confirmed cases in the United States in a single day, which is close to the highest record of 77,299 new cases in a single day on July 16. As of 17:00 on October 23, US Eastern Time (5:00 on the 24th, Beijing time), the number of confirmed cases of new coronary pneumonia in the United States exceeded 8.46 million, reaching 8,468,802, and 223,730 deaths.

And the diagnosis in a single day is about to approach the highest recordcrucial momentHowever, the meetings of the White House New Crown Working Group have to be reduced to once a week. Fauci also said that Trump has not participated in the working group meetings for several months.

  AstraZeneca resumes laboratory testing of new crown vaccine JohnsonToo soon

This Friday, Eastern Time, AstraZeneca said: AstraZeneca and Oxford University jointly cooperated with the laboratory test of the new crown pneumonia vaccine AZD1222, which has been resumed after the safety of the US, UK, Brazil, South Africa and Japan regulatory agencies. . The U.S. Food and Drug Administration reviewed all safety data from global trials,AuthorizationResume Phase III trial.

It is reported that American food and drugmanagementThe FDA has concluded investigations into two cases of candidate vaccines that may cause neurological side effects and informed AstraZeneca on Friday afternoon that thethe companyIt can continue to test its new coronavirus vaccine candidate in the United States. The FDA concluded that the vaccine is not the cause of neurological side effects, although the link cannot be ruled out.

After the news was released, AstraZeneca’s stock price short-termPull up, Once rose 0.84%, and closed slightly up 0.08%.

According to the Financial Times, the vaccine agreement allows AstraZeneca to obtain more thancost20%profit

On the 21st of this month, a number of foreign media reported that Brazil’s National Health Supervision Agency stated that one of the participants participated in Oxford and AstraZeneca (AZN.US)Cooperative research and developmentThe 28-year-old Brazilian volunteer in the clinical trial of the new crown vaccine died, but the trial was still allowed to continue. It is worth noting that Bloomberg quoted a source familiar with the matter on October 21 that the dead volunteer had not been vaccinated.

In response, AstraZeneca China responded, “Because we strictly abide by medical confidentiality and clinical trial regulations, we cannot comment on individual cases in the ongoing new crown vaccine trial. We can confirm that all necessary review procedures have been followed.”

As early as September of this year, AstraZeneca stopped the trial globally because of an illness of a British participant.The symptom of this subject from the United Kingdom was “perforating myelitis”. This inflammation can be caused by a viral infection. In severe cases, it can cause inflammation of the lower limbs of the spinal cord.feelThe nervous, motor and autonomic nervous systems are out of control. Subsequently, AstraZeneca resumed research in the United Kingdom, Brazil, South Africa and India, but clinical trials in the United States did not resume.

This Friday, Eastern Time, the Washington Post reported thatJohnsonThe new crown vaccine trial will also resume soon.

Shortly after that day, Johnson & Johnson said that Johnson & Johnson is discussing with the regulatory agencies of various countries to resume vaccine trials and will resume the third phase of the new crown vaccine trial. It is expected to restart the vaccine trial on Monday or Tuesday.

Johnson & Johnson also predicts that the efficacy data of the new coronavirus vaccine trial in the United States will be released at the end of 2020 or early 2021.

Johnson & Johnson shares rose slightly on Friday.

  Bill Gates: Even after a yearThe world will not return to normal

according toTencentTechnology News on October 23,MicrosoftCo-founderBill Gates(Bill Gates) predicted in a talk show on Friday that despite the global efforts to contain the spread of the new crown pneumonia epidemic, even a year later, the world will not return to normal.

Gates said, “Sadly, as we enter the fall, the number of cases and deaths will rise again. The reason these numbers are so high is partly because our response was very bad.”

But Gates also believes that in the fall of 2021, the situation in the United States will be greatlyimprove.Gates said, “ManyserviceThe work of the industry can be put in place again, and the school can also return to the original place. But during this period, we are also facing risks. “

  WHO: The number of cases in too many countries is increasing exponentially The global epidemic is at a critical juncture

According to CCTV News, on October 23 local time, the WHO held a routine press conference for new crown pneumonia. WHO Director-General Tedros Adhanom Ghebreyesus said that the global epidemic is at a critical juncture, especially in the northern hemisphere. The next few months will be very difficult, and some countries are on a dangerous track.

Tan Desai emphasized that the number of cases in too many countries has increased exponentially, causing hospitals and intensive care units to become or exceed saturation, and it is only October.Tan Desai urged leaders of all countries to take immediate action to prevent more unnecessary deaths and avoid basicmedical serviceCrash or school closed again.

  The stimulus deadlock continues

  U.S. stocks end their weekly gains

Despite the release of positive news related to vaccines, the deadlock of the stimulus plan still drags down the trend of US stocks.

On Friday, local time, the Speaker of the US House of Representatives, Pelosi, expressed the hope that another stimulus bill could be introduced.White House NewssecretaryMcNerney also said that it is “very” possible to reach a stimulus agreement.

But shortly after that day, US Treasury Secretary Steven Mnuchin stated that the Speaker of the House of Representatives Nancy Pelosi was working hard to reach an agreement, but there were still big differences in the negotiations between the two sides.

United StatesNational economyThe consultant Kudlow also bluntly said that the stimulus plan negotiations are not progressing very quickly.

After the US stock market, the assistant speaker of the House of Representatives of the United States Congress said that Speaker Pelosi hopes to reach an agreement with the White House on a stimulus plan soon. If the donkey and elephant parties make progress in the negotiations, Speaker Pelosi will again talk to Finance Minister Mnuchin.

In the context of the lack of progress in the stimulus plan, the three major US stock indexes were mixed last night. The S&P closed up 0.35% and fell 0.52% this week; the Nasdaq closed up 0.37% and fell 1.06% this week; the Dow closed down 0.1%, this week has fallen 0.94%.

The Dow and S&P 500 index ended their three consecutive weekly gains.

(Article source: ChinafundNewspaper)

(Editor in charge: DF064)

Solemnly declare: The purpose of this information released by Oriental Fortune.com is to spread more information and has nothing to do with this stand.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.